APMD (Apnimed) Market Cap: $949.99 Mil (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APMD Apnimed Inc APMD
8 GF Score
Price $25.00
View Full Analysis

What is Apnimed Market Cap?

Apnimed APMD +13.64% 8 Market Cap is $949.99 Mil as of Aug. 02, 2026. GuruFocus rates APMD with a GF Score™ of 8/100. Among 1,423 Biotechnology companies, Apnimed ranks better than 79.76% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Apnimed's share price for the quarter that ended in Mar. 2026 was $0. Apnimed's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 38.00 Mil. Therefore, Apnimed's market cap for the quarter that ended in Mar. 2026 was $0.00 Mil.

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Apnimed's Enterprise Value for Today is $668.02 Mil.


Apnimed  (NAS:APMD) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Apnimed Market Cap Related Terms


Apnimed Market Cap Historical Data

* Premium members only.

The historical data trend for Apnimed's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apnimed Market Cap Chart

Apnimed Annual Data
Trend Dec24 Dec25
Market Cap
0.00 0.00

Apnimed Quarterly Data
Dec24 Mar25 Dec25 Mar26
Market Cap 0.00 0.00 0.00 0.00

APMD vs : Market Cap Comparison

For the Biotechnology subindustry, Apnimed's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apnimed Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apnimed's Market Cap distribution charts can be found below:

* The bar in red indicates where Apnimed's Market Cap falls into.


APMD
8GF Score
Apnimed Inc APMD
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apnimed Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Apnimed's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=$0*26.811
=$0.00

Apnimed's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=$0*38.000
=$0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $949.99 Mil mean?
Apnimed (APMD) has a Market Cap of $949.99 Mil as of Aug. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Apnimed and its competitors. According to the industry distribution chart, Apnimed ranks #288 out of 1423 companies in the Biotechnology industry, placing it in the top 20.2%.
Is Apnimed's Market Cap too high?
Apnimed's current Market Cap is $949.99 Mil. The Biotechnology industry median Market Cap is 112.87. Apnimed's value of $949.99 Mil is 741.7% above this industry median. Based on the distribution chart, Apnimed ranks #288 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's Market Cap compare to ?
According to the Biotechnology industry distribution chart, Apnimed ranks #288 out of 1423 companies for Market Cap. This places Apnimed in the top 20% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.87. Apnimed's value of $949.99 Mil is 741.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.87, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apnimed's current Market Cap of $949.99 Mil is 741.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Apnimed and its competitors. For the Biotechnology industry, the median Market Cap is 112.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apnimed's current Market Cap is $949.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current Market Cap of $949.99 Mil. The current Market Cap is $949.99 Mil and 741.7% above the Biotechnology industry median of 112.87. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Apnimed (APMD), the current Market Cap is $949.99 Mil as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apnimed Business Description

Comparable Companies
Address 39 John F. Kennedy Street, 4th Floor, Cambridge, MA, USA, 02138
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score

Get the complete analysis for APMD

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price